This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jan 17;9(2):65.

doi: 10.1038/nrclinonc.2011.210.

Gynecological cancer: True progress in ovarian cancer or just the tip of the iceberg?

Lisa Hutchinson

PMID: 22249444
DOI: 10.1038/nrclinonc.2011.210

Comment

Gynecological cancer: True progress in ovarian cancer or just the tip of the iceberg?

Lisa Hutchinson. Nat Rev Clin Oncol. 2012.

. 2012 Jan 17;9(2):65.

doi: 10.1038/nrclinonc.2011.210.

Author

Lisa Hutchinson

PMID: 22249444
DOI: 10.1038/nrclinonc.2011.210

No abstract available

PubMed Disclaimer

Comment on

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF, Vergote I. Gotlieb WH, et al. Lancet Oncol. 2012 Feb;13(2):154-62. doi: 10.1016/S1470-2045(11)70338-2. Epub 2011 Dec 20. Lancet Oncol. 2012. PMID: 22192729 Clinical Trial.

References

1. Lancet Oncol. 2012 Feb;13(2):154-62 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.